Use of Continuous Wound Infusion of Bupivacaine for Analgesia Following Axillary Clearance Surgery
Recruitment status was Recruiting
Axillary clearance forms part of the surgical armamentarium for the treatment of breast cancer. Although the introduction of sentinel lymph node mapping and dissection has allowed for the decreased use of axillary clearance, it remains a frequently performed operation. Axillary clearance is associated with moderate postoperative pain.
We hypothesize that a continuous wound infusion of 0.2% Bupivacaine at 4ml/hr would provide superior analgesia, when compared to standard opioid-based analgesia, in patients undergoing axillary lymph node clearance surgery.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Does Continuous Wound Infusion of 0.2% Bupivacaine Provide Superior Analgesia Compared to Standard Opioid-based Therapy in Patients Following Axillary Clearance Surgery?|
- Pain on abducting the arm on the operative side to 90 degrees as measured using a 100mm visual analogue scale at 6 hours following surgery. [ Time Frame: 6 hours postoperatively ] [ Designated as safety issue: No ]
- Pain (at rest and on movement) in the recovery room and at 6, 24 and 48 hours after surgery. [ Time Frame: 48 hours postoperatively ] [ Designated as safety issue: No ]
- Cumulative Oxycodone consumption at 6, 24 and 48 hours after surgery [ Time Frame: 48 hours postoperatively ] [ Designated as safety issue: No ]
- incidence of nausea and vomiting [ Time Frame: 48 hours postoperatively ] [ Designated as safety issue: No ]
|Study Start Date:||August 2010|
|Estimated Study Completion Date:||October 2011|
|Estimated Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
Patients will receive intraoperative wound soakage with 20ml of 0.5% bupivacaine with adrenaline by the surgeon before closure and receive a continuous infusion of 4ml/hr of 0.2% bupivacaine delivered by an elastomeric pump the catheter of which will be placed by the surgeon in the wound before closure. Postoperative anlagesia will be provided with oxycodone, paracetamol and diclofenac.
intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
No Intervention: Control
Patients will receive morphine up to 0.1mg/kg intraoperatively. Postoperative analgesia will be provided with oxycodone, paracetamol and diclofenac.
The study will take the form of a prospective randomised clinical trial. The following assessment tools will be used
- The visual analogue scale (VAS) consists of a 100 mm horizontal line with the two end points labelled "no pain" and "worst pain ever". Patients are asked to mark on the line a point that corresponds to the level of pain intensity they feel. The score is obtained by measuring the distance (mm) from the left end of the line.
- The short-form McGill Pain Questionnaire (SF-MPQ) consists of 15 representative words from the sensory and affective categories of the standard McGill Pain Questionnaire. It also includes the present pain intensity and a VAS to provide overall indices of pain intensity. It has been shown to be sensitive to clinical changes brought about by various interventions, postoperative analgesic drugs (6).
- The Pain Catastrophising Score (PCS) is a 13 item instrument which asks patient to reflect on past painful experiences, and to indicate the degree to which they experienced each of these 13 thoughts or feelings, on 5-point scales with the end points; 0 = not at all, 4 = all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification and helplessness (7).
- The Hospital Anxiety and Depression Score (HADS) is a 14-item scale, which screens for these, the two most common disturbances encountered in a medical setting (8).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01314144
|Contact: Denise M McCarthy, MB FCARCSI||353 87 email@example.com|
|Contact: Brian O'Donnell, MD FCARCSI||353 21 firstname.lastname@example.org|
|Cork Universtiy Hospital||Recruiting|
|Principal Investigator: Denise M McCarthy, MB FCARCSI|
|Principal Investigator:||Denise M McCarthy, MB FCARCSI||Cork Universtiy Hospital|